The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh ImpactUpdated×2•Originally published 6 May 2026•Updated 6 May 2026•

1 min read

TG Therapeutics Stock Surges as H.C. Wainwright Raises Price Target to $70

Key Facts

1H.C. Wainwright raised its price target for TGTX to $70, suggesting a potential 76.1% upside.

28 days ago

Version History

1 additional source confirmed this story

Version 228 days ago

Version 128 days ago

H.C. Wainwright has significantly raised its price target for TG Therapeutics (TGTX) to $70, implying a potential upside of 76.1%. The revision follows a robust Q1 2026 performance where the company reported revenues of approximately $205 million. This growth was primarily fueled by the success of its flagship product, BRIUMVI, which generated $195 million in U.S. net revenue. Consequently, TG Therapeutics has upgraded its full-year global revenue guidance to approximately $925 million. The market responded bullishly to the news, with the stock price surging 10.51% to hit a new 52-week high. Analysts view this upward revision as a testament to the company's strengthening commercial position in the biotechnology sector.